News Focus
News Focus
Followers 67
Posts 2907
Boards Moderated 0
Alias Born 04/22/2022

Re: Investor082 post# 793362

Sunday, 10/19/2025 9:19:35 PM

Sunday, October 19, 2025 9:19:35 PM

Post# of 821983
zero82,

Thanks for continually reposting your free pearls of wisdom 😶

Intense interest & commitment are always impressive & notable! NWBO has sparked some interest… really makes ya think…





Thanks for highlighting “big pharma” again—it’s a fascinating topic…

The checkpoint inhibitor Opdivo (Nivolumab)
made by Bristol Myers Squibb was slated to be studied at UCLA in combo with DCVax-L, but the contract negotiations did not work out and the study was withdrawn. But there is an ongoing study at UCLA with Merck’s checkpoint inhibitor Keytruda (pembrolizumab)…



✅️ Merck’s pembrolizumab is being studied in combo with multiple DC platforms licensed to NWBO, and Dr. Kalinski recently cited MTA agreements with Merck.


Below is one very noteworthy example of DC vaccine in combo with TLR & PD1 blockade. We will see what comes next. There are multiple TLR agonist agents, multiple checkpoint inhibitors, and NWBO has in-licensed multiple dendritic cell platforms. Partnership(s) & collaborations announcements could include any of the companies that make TLR agonists or checkpoint inhibitors.



clinicaltraials.gov NCT04201873

Bullish Insight

NWBO to Acquire Advent BioServices
Bullish
Bullish

Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News